I'm LongbridgeAI, I can summarize articles.Fate Therapeutics granted inducement equity awards to new non-executive hires on August 1, 2026. The package includes 37,300 non-qualified stock options at $2.45 per share and 45,300 restricted stock units (RSUs). Options vest over four years with a 25% cliff after one year, while RSUs vest in annual 25% installments subject to continued employment.
- Fate Therapeutics disclosed August 1, 2026 inducement equity awards to newly hired non-executive employees. * Granted non-qualified stock options for 37,300 shares at an exercise price of $2.45, set at the July 31 close. * Awarded RSUs covering 45,300 shares to two hires, including the option recipient. * Options vest over four years: 25% after one year, then monthly over 36 months. * RSUs vest over four years in 25% annual installments, subject to continued employment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031605PRIMZONEFULLFEED9801906) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)